Pharmaceutical Products – Clindamycin + Benzoylperoxide
Titre original de l'avis
Germany – Pharmaceutical products – Arzneimittelrabattverträge mit Beitrittsoption
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
30 / 100
Facteurs de risque
The notice explicitly states it is not a public procurement under EU directives. This may limit suppliers' legal recour...
No estimated value or budget provided. Unknown volume or pricing expectations could lead to wasted effort or unprofitab...
No procurement documents available
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Supply of pharmaceutical product with active ingredient Clindamycin + Benzoylperoxide
- Framework agreement with option for additional parties to join
Afficher le résumé complet
This is a voluntary publication for a framework agreement (with option to join) for the supply of pharmaceutical products containing Clindamycin and Benzoylperoxide. The buyer is BARMER, a German health insurance company. The tender is explicitly not subject to EU procurement law, despite using an 'open procedure' label. Only one lot is defined, covering a single active ingredient combination. The deadline is in 2028, leaving ample time. No estimated value, award criteria, or formal eligibility requirements are provided in the notice. Procurement documents are available online.
Risques
The notice explicitly states it is not a public procurement under EU directives. This may limit suppliers' legal recour...
No estimated value or budget provided. Unknown volume or pricing expectations could lead to wasted effort or unprofitab...
No procurement documents available
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Ability to supply the specified pharmaceutical product
- Compliance with German pharmaceutical regulations (implied)
Acheteur
Localisation
Wuppertal, DEU
Site web
Identifiant
992-80322-57
Activité
Health
Lots (1)
LOT-0000
Pharmaceutical Products – Clindamycin + Benzoylperoxide
Framework agreement for the supply of pharmaceutical products with the active ingredient combination Clindamycin and Benzoylperoxide. The agreement includes an option for additional parties to join. Duration from July 2026 to June 2028, with a possible 3-month extension. Place of performance is Wuppertal, Germany.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Ein Los Wirkstoff Clindamycin + Benzoylperoxid
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Arzneimittelrabattverträge mit Beitrittsoption
Description TED originale
Ein Los Wirkstoff Clindamycin + Benzoylperoxid
Détails de la procédure
- Date de publication
- 18 May 2026
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 341463-2026
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
30 / 100
Facteurs de risque
The notice explicitly states it is not a public procurement under EU directives. This may limit suppliers' legal recour...
No estimated value or budget provided. Unknown volume or pricing expectations could lead to wasted effort or unprofitab...
No procurement documents available
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications